

SUPPLEMENTARY DATA

REIMBURSEMENT BY DRUG PROGRAMME TYPE IN POLAND ESTIMATES TO 2015

Appendix. 1. Reimbursement by drug programme type in Poland estimates to 2015, [USD].

Lp.	Number of drug program	Name of drug program	Type	Values of reimbursement realised by the NHF, [USD]
1	B.9.	Treatment of breast cancer	oncological	78 485 573
2	B.29.	Treatment of multiple sclerosis	non-oncological	54 647 054
3	B.2.	Treatment of chronic viral hepatitis C	non-oncological	38 244 466
4	B.10.	Treatment of renal cell carcinoma	oncological	33 328 329
5	B.14.	Chronic myeloid leukemia	oncological	31 779 778
6	B.54.	Lenalidomide in the treatment of refractory or relapsed multiple myeloma	oncological	28 788 394
7	B.71.	Interferon-free treatment of chronic viral hepatitis C	non-oncological	28 727 888
8	B.4.	Treatment of advanced colorectal cancer	oncological	27 788 808
9	B.33.	Treatment of rheumatoid arthritis and aggressive juvenile idiopathic arthritis	non-oncological	27 346 493
10	B.3.	Treatment of gastrointestinal stromal tumours (GIST)	oncological	21 902 549
11	B.1.	Treatment of chronic viral hepatitis B	non-oncological	21 200 573
12	B.36.	Treatment of beneficiaries with severe active ankylosing spondylitis with TNF alfa inhibitors	non-oncological	18 834 410
13	B.31.	Treatment of pulmonary arterial hypertension (PAH)	non-oncological	18 695 466
14	B.59.	Treatment of melanoma of skin or mucosal melanoma	oncological	17 534 442
15	B.12.	Treatment of malignant lymphomas	oncological	16 893 316
16	B.48.	Treatment of skin melanoma	oncological	15 093 385
17	B.46.	Treatment of multiple sclerosis after first line treatment failure or rapidly evolving severe multiple sclerosis	non-oncological	12 716 300
18	B.23.	Treatment of Gaucher's disease	non-oncological	11 937 381

Lp.	Number of drug program	Name of drug program	Type	Values of reimbursement realised by the NHF, [USD]
19	B.6.	Treatment of non-small cell lung cancer	oncological	10 367 449
20	B.35.	Treatment of aggressive psoriatic arthritis	non-oncological	9 335 776
21	B.25.	Treatment of mucopolisaccharosis type II (Hunter syndrome)	non-oncological	9 109 280
22	B.15.	Haemorrhages prevention in children with haemophilia A and B	non-oncological	8 863 718
23	B.22.	Treatment of Pompe disease	non-oncological	7 973 901
24	B.32.	Treatment of Crohn's disease (CD)	non-oncological	7 751 211
25	B.56.	Treatment of castration-resistant prostate cancer	oncological	7 642 649
26	B.39.	Treatment of secondary hyperparathyroidism in haemodialysis patients	non-oncological	7 641 937
27	B.40.	Prevention of respiratory syncytial virus infections	non-oncological	5 777 221
28	B.19.	Treatment of dwarf children with somatotropin pituitary insufficiency	non-oncological	5 688 023
29	B.44.	Treatment of severe ige-dependent allergic asthma with omalizumab	non-oncological	5 313 629
30	B.50.	Treatment of patients with advanced ovarian cancer	oncological	5 179 768
31	B.8.	Treatment of soft tissue sarcomas	oncological	3 674 907
32	B.47.	Treatment of moderate and severe plaque psoriasis	non-oncological	3 646 576
33	B.67.	Treatment with immunoglobulin transfusions in neurologic diseases	non-oncological	3 473 645
34	B.24.	Treatment of Hurler disease	non-oncological	2 898 332
35	B.5.	Treatment of hepatocellular carcinoma	oncological	2 525 210
36	B.62.	Treatment of primary immune deficiency (PID) in adult patients	non-oncological	2 361 726
37	B.28.	Treatment of focal dystonia and hemifacial spasm	non-oncological	2 140 716
38	B.17.	Treatment of primary immunodeficiency in children	non-oncological	2 023 049
39	B.26.	Treatment of mucopolysaccharidosis type IV (Maroteaux-Lamy syndrome)	non-oncological	1 756 214
40	B.58.	Treatment of advanced gastric cancer	oncological	1 483 182
41	B.70.	Treatment of neovascular (exudative) form of age-related macular degeneration (AMD)	non-oncological	1 220 918
42	B.53.	Treatment of well-differentiated neuroendocrine pancreatic carcinoma	oncological	1 163 269
43	B.20.	Treatment of dwarf children with severe primary igf-1 deficiency	non-oncological	1 065 371

Lp.	Number of drug program	Name of drug program	Type	Values of reimbursement realised by the NHF, [USD]
44	B.42.	Treatment of dwarf children with Turner syndrome (TS)	non-oncological	1 043 551
45	B.68.	Treatment of pulmonary arterial hypertension with sildenafil, epoprostenol and macitentan (PAH)	non-oncological	1 009 212
46	B.60.	Treatment of Gaucher's disease type 1	non-oncological	996 794
47	B.37.	Treatment of anaemia in the course of chronic renal insufficiency	non-oncological	917 417
48	B.55.	Treatment of patients with ulcerative colitis	non-oncological	897 512
49	B.57.	Treatment of upper limb spasticity after stroke with botulinum toxin type A	non-oncological	877 637
50	B.65.	Treatment of Philadelphia chromosome-positive (Ph+) chronic acute lymphoblastic leukemia with dasatinib	oncological	794 456
51	B.30.	Treatment of spasticity in cerebral palsy	non-oncological	780 659
52	B.27.	Treatment of chronic lung infections in beneficiaries with mucoviscidosis	non-oncological	650 177
53	B.69.	Treatment with paricalcitol of secondary hyperparathyroidism in haemodialysis patients	non-oncological	512 270
54	B.49.	Oral treatment of iron overload states in the body	non-oncological	511 029
55	B.66.	Treatment with bexarotene of mycosis fungoides or Sézary syndrome	non-oncological	427 935
56	B.18.	Treatment of premature sexual maturation in children	non-oncological	367 710
57	B.52.	Treatment of squamous cell cancer of head and neck in combination with radition therapy in locally advanced disease	oncological	365 720
58	B.72.	Treatment of melanoma with combination therapy with dabrafenib and trametinib	oncological	315 583
59	B.63.	Treatment of non-small cell lung cancer with afatinib	oncological	260 392
60	B.43.	Treatment of viral hepatitis B in beneficiaries after transplantations or in beneficiaries with lymphomas, treated with rituximab	non-oncological	208 648
61	B.41.	Treatment of Prader-Willi syndrome	non-oncological	177 211
62	B.38.	Treatment of dwarf children with chronic kidney failure	non-oncological	109 261
63	B.64.	Treatment with growth hormone of dwarf children born too small in relation to pregnancy length (sga or iugr)	non-oncological	57 541
64	B.21.	Treatment of severe familial hyperhomocysteinemia	non-oncological	50 563
65	B.75.	Treatment of active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa)	non-oncological	34 340
66	B.74.	Treatment of chronic thromboembolic pulmonary hypertension (cteph)	non-oncological	27 247
67	B.73.	Treatment of neurogenic detrusor overactivity	non-oncological	10 860

Lp.	Number of drug program	Name of drug program	Type	Values of reimbursement realised by the NHF, [USD]
68	B.61.	Treatment of nephropathic juvenile cystinosis	non-oncological	8 197
69	B.76.	Treatment of tyrosinemia type 1 (ht-1)	non-oncological	0

Source: own elaboration, NHF data.

REIMBURSEMENT BY DRUG PROGRAMME TYPE IN POLAND ESTIMATES TO 2016

Appendix. 2. Reimbursement by drug programme type in Poland estimates to 2016, [USD].

Lp.	Number of drug program	Name of drug program	Type	Values of reimbursement realised by the NHF, [USD]
1	B.71.	Interferon-free treatment of chronic viral hepatitis C	non-oncological	116 043 837
2	B.9.	Treatment of breast cancer	oncological	82 626 134
3	B.29.	Treatment of multiple sclerosis	non-oncological	58 685 457
4	B.10.	Treatment of renal cell carcinoma	oncological	34 788 764
5	B.33.	Treatment of rheumatoid arthritis and aggressive juvenile idiopathic arthritis	non-oncological	32 656 860
6	B.54.	Lenalidomide in the treatment of refractory or relapsed multiple myeloma	oncological	31 718 703
7	B.4.	Treatment of advanced colorectal cancer	oncological	31 532 468
8	B.14.	Chronic myeloid leukemia	oncological	31 292 976
9	B.3.	Treatment of gastrointestinal stromal tumours (GIST)	oncological	23 254 701
10	B.36.	Treatment of beneficiaries with severe active ankylosing spondylitis with TNF alfa inhibitors	non-oncological	19 035 602
11	B.1.	Treatment of chronic viral hepatitis B	non-oncological	18 998 771
12	B.31.	Treatment of pulmonary arterial hypertension (PAH)	non-oncological	17 609 026
13	B.12.	Treatment of malignant lymphomas	oncological	17 211 421
14	B.70.	Treatment of neovascular (exudative) form of age-related macular degeneration (AMD)	non-oncological	16 524 091
15	B.46.	Treatment of multiple sclerosis after first line treatment failure or rapidly evolving severe multiple sclerosis	non-oncological	16 387 806

Lp.	Number of drug program	Name of drug program	Type	Values of reimbursement realised by the NHF, [USD]
16	B.23.	Treatment of Gaucher's disease	non-oncological	12 247 283
17	B.48.	Treatment of skin melanoma	oncological	12 086 553
18	B.59.	Treatment of melanoma of skin or mucosal melanoma	oncological	11 564 784
19	B.67.	Treatment with immunoglobulin transfusions in neurologic diseases	non-oncological	10 933 407
20	B.15.	Haemorrhages prevention in children with haemophilia A and B	non-oncological	10 751 162
21	B.56.	Treatment of castration-resistant prostate cancer	oncological	9 582 437
22	B.35.	Treatment of aggressive psoriatic arthritis	non-oncological	9 240 550
23	B.6.	Treatment of non-small cell lung cancer	oncological	8 596 134
24	B.22.	Treatment of Pompe disease	non-oncological	8 261 478
25	B.25.	Treatment of mucopolisaccharosis type II (Hunter syndrome)	non-oncological	8 119 287
26	B.68.	Treatment of pulmonary arterial hypertension with sildenafil, epoprostenol and macitentan (PAH)	non-oncological	7 314 161
27	B.72.	Treatment of skin cancer with dabrafenib	oncological	7 254 412
28	B.32.	Treatment of Crohn's disease (CD)	non-oncological	7 151 874
29	B.50.	Treatment of patients with advanced ovarian cancer	oncological	6 341 163
30	B.19.	Treatment of dwarf children with somatotropin pituitary insufficiency	non-oncological	5 974 292
31	B.44.	Treatment of severe ige-dependent allergic asthma with omalizumab	non-oncological	5 785 056
32	B.39.	Treatment of secondary hyperparathyroidism in haemodialysis patients	non-oncological	5 719 989
33	B.40.	Prevention of respiratory syncytial virus infections	non-oncological	5 717 411
34	B.62.	Treatment of primary immune deficiency (PID) in adult patients	non-oncological	5 268 223
35	B.2.	Treatment of chronic viral hepatitis C	non-oncological	5 110 817
36	B.8.	Treatment of soft tissue sarcomas	oncological	4 140 049
37	B.47.	Treatment of moderate and severe plaque psoriasis	non-oncological	4 128 566
38	B.5.	Treatment of hepatocellular carcinoma	oncological	3 257 092
39	B.24.	Treatment of Hurler disease	non-oncological	3 044 951
40	B.77.	Treatment of resistant and relapse lymphomas cd30+	non-oncological	2 789 296
41	B.69.	Treatment with paricalcitol of secondary hyperparathyroidism in haemodialysis patients	non-oncological	2 301 767

Lp.	Number of drug program	Name of drug program	Type	Values of reimbursement realised by the NHF, [USD]
42	B.28.	Treatment of focal dystonia and hemifacial spasm	non-oncological	2 273 806
43	B.17.	Treatment of primary immunodeficiency in children	non-oncological	2 072 179
44	B.74.	Treatment of chronic thromboembolic pulmonary hypertension (cteph)	non-oncological	1 913 521
45	B.58.	Treatment of advanced gastric cancer	oncological	1 726 773
46	B.63.	Treatment of non-small cell lung cancer with afatinib	oncological	1 345 313
47	B.53.	Treatment of well-differentiated neuroendocrine pancreatic carcinoma	oncological	1 273 548
48	B.65.	Treatment of Philadelphia chromosome-positive (Ph+) chronic acute lymphoblastic leukemia with dasatinib	oncological	1 108 758
49	B.60.	Treatment of Gaucher's disease type 1	non-oncological	1 080 163
50	B.42.	Treatment of dwarf children with Turner syndrome (TS)	non-oncological	1 073 089
51	B.20.	Treatment of dwarf children with severe primary igf-1 deficiency	non-oncological	1 064 833
52	B.57.	Treatment of upper limb spasticity after stroke with botulinum toxin type A	non-oncological	963 595
53	B.76.	Treatment of tyrosinemia type 1 (ht-1)	non-oncological	938 053
54	B.26.	Treatment of mucopolysaccharidosis type IV (Maroteaux-Lamy syndrome)	non-oncological	925 455
55	B.30.	Treatment of spasticity in cerebral palsy	non-oncological	852 478
56	B.37.	Treatment of anaemia in the course of chronic renal insufficiency	non-oncological	802 289
57	B.66.	Treatment with bexarotene of mycosis fungoides or Sézary syndrome	non-oncological	764 950
58	B.27.	Treatment of chronic lung infections in beneficiaries with mucoviscidosis	non-oncological	743 424
59	B.55.	Remission induction in ulcerative colitis	non-oncological	704 633
60	B.49.	Oral treatment of iron overload states in the body	non-oncological	615 274
61	B.52.	Treatment of squamous cell cancer of head and neck in combination with radiation therapy in locally advanced disease	oncological	520 243
62	B.18.	Treatment of premature sexual maturation in children	non-oncological	430 970
63	B.75.	Treatment of active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa)	non-oncological	429 808
64	B.43.	Treatment of viral hepatitis B in beneficiaries after transplantations or in beneficiaries with lymphomas, treated with rituximab	non-oncological	218 676
65	B.41.	Treatment of children with Prader-Willi syndrome	non-oncological	188 621
66	B.64.	Treatment with growth hormone of dwarf children born too small in relation to pregnancy length (sga lub)	non-oncological	174 771

Lp.	Number of drug program	Name of drug program	Type	Values of reimbursement realised by the NHF, [USD]
		iugr)		
67	B.79.	Treatment of chronic lymphocytic leukemia with obinutuzumab	non-oncological	127 420
68	B.38.	Treatment of dwarf children with chronic kidney failure	non-oncological	90 410
69	B.21.	Treatment of severe familial hyperhomocysteinemia	non-oncological	55 864
70	B.73.	Treatment of neurogenic detrusor overactivity	non-oncological	45 940
71	B.80.	Maintenance therapy with olaparib of patients with relapsed platinum-sensitive advanced ovarian cancer, fallopian tube cancer or primary peritoneal cancer	oncological	41 756
72	B.61.	Treatment of nephropathic juvenile cystinosis	non-oncological	21 130
73	B.78.	Treatment of primary immune deficiencies in adult patients with normal human immunoglobulin administered with human recombinant hyaluronidase	non-oncological	20 118

Source: own elaboration, NHF data.

REIMBURSEMENT BY DRUG PROGRAMME TYPE IN POLAND ESTIMATES TO 2017

Appendix. 3. Reimbursement by drug programme type in Poland estimates to 2017, [USD].

Lp.	Number of drug program	Name of drug program	Type	Values of reimbursement realised by the NHF, [USD]
1	B.9.	Treatment of breast cancer	oncological	118 276 084
2	B.71.	Interferon-free treatment of chronic viral hepatitis C	non-oncological	109 178 658
3	B.29.	Treatment of multiple sclerosis	non-oncological	66 378 300
4	B.54.	Treatment of refractory or relapsed multiple myeloma	oncological	36 985 168
5	B.10.	Treatment of renal cell carcinoma	oncological	35 019 759
6	B.4.	Treatment of advanced colorectal cancer	oncological	34 302 745

Lp.	Number of drug program	Name of drug program	Type	Values of reimbursement realised by the NHF, [USD]
7	B.33.	Treatment of rheumatoid arthritis and aggressive juvenile idiopathic arthritis	non-oncological	33 284 884
8	B.14.	Treatment of chronic myeloid leukemia	oncological	28 998 737
9	B.59.	Treatment of skin or mucosal melanoma	oncological	23 710 717
10	B.3.	Treatment of gastrointestinal stromal tumours (GIST)	oncological	21 657 287
11	B.36.	Treatment of beneficiaries with severe active ankylosing spondylitis with TNF alfa inhibitors	non-oncological	19 046 874
12	B.46.	Treatment of multiple sclerosis after first line treatment failure or rapidly evolving severe multiple sclerosis	non-oncological	18 823 968
13	B.31.	Treatment of pulmonary arterial hypertension (PAH)	non-oncological	18 700 871
14	B.70.	Treatment of neovascular (exudative) form of age-related macular degeneration (AMD)	non-oncological	18 103 475
15	B.12.	Treatment of malignant lymphomas	oncological	16 949 679
16	B.1.	Treatment of chronic viral hepatitis B	non-oncological	16 726 079
17	B.67.	Treatment with immunoglobulin transfusions in neurologic diseases	non-oncological	14 663 919
18	B.72.	Treatment of melanoma with combination therapy with dabrafenib and trametinib	oncological	14 174 447
19	B.56.	Treatment of castration-resistant prostate cancer	oncological	13 387 547
20	B.23.	Treatment of Gaucher's disease type 1	non-oncological	13 357 659
21	B.15.	Haemorrhages prevention in children with haemophilia A and B	non-oncological	11 488 207
22	B.68.	Treatment of pulmonary arterial hypertension with sildenafil, epoprostenol and macitentan (PAH)	non-oncological	10 770 605
23	B.35.	Treatment of aggressive psoriatic arthritis	non-oncological	10 314 324
24	B.22.	Treatment of Pompe disease	non-oncological	9 579 385
25	B.77.	Treatment of resistant and relapse lymphomas cd30+	oncological	9 355 582

Lp.	Number of drug program	Name of drug program	Type	Values of reimbursement realised by the NHF, [USD]
26	B.32.	Treatment of Crohn's disease (CD)	non-oncological	8 454 469
27	B.48.	Treatment of skin melanoma	oncological	8 210 473
28	B.6.	Treatment of non-small cell lung cancer	oncological	7 614 113
29	B.50.	Treatment of patients with advanced ovarian cancer	oncological	7 409 942
30	B.44.	Treatment of severe ige-dependent allergic asthma with omalizumab	non-oncological	6 782 211
31	B.40.	Prevention of respiratory syncytial virus infections	non-oncological	6 562 042
32	B.25.	Treatment of mucopolisacharosis type II (Hunter syndrome)	non-oncological	6 506 251
33	B.19.	Treatment of dwarf children with somatotropin pituitary insufficiency	non-oncological	6 401 367
34	B.62.	Treatment of primary immunodeficiency in adults	non-oncological	5 757 874
35	B.47.	Treatment of moderate and severe plaque psoriasis	non-oncological	5 223 983
36	B.8.	Treatment of soft tissue sarcomas	oncological	4 288 962
37	B.39.	Treatment of secondary hyperparathyroidism in haemodialysis patients	non-oncological	3 950 574
38	B.74.	Treatment of chronic thromboembolic pulmonary hypertension (cteph)	non-oncological	3 298 036
39	B.5.	Treatment of hepatocellular carcinoma	oncological	3 283 906
40	B.79.	Treatment of chronic lymphocytic leukemia with obinutuzumab	oncological	3 071 287
41	B.24.	Treatment of Hurler disease	non-oncological	2 935 966
42	B.63.	Treatment of non-small cell lung cancer with afatinib and nintedanib	oncological	2 468 621
43	B.28.	Treatment of focal dystonia and hemifacial spasm	non-oncological	2 392 192
44	B.81.	Treatment of primary mielofibrosis and secondary mielofibrosis in the course of polycyhemias and thrombocytosis	oncological	2 382 702

Lp.	Number of drug program	Name of drug program	Type	Values of reimbursement realised by the NHF, [USD]
45	B.80.	Maintenance therapy with olaparib of patients with relapsed platinum-sensitive advanced ovarian cancer, fallopian tube cancer or primary peritoneal cancer	oncological	2 329 554
46	B.17.	Treatment of primary immunodeficiency in children	non-oncological	2 290 480
47	B.2.	Treatment of chronic viral hepatitis c	non-oncological	2 198 818
48	B.58.	Treatment of advanced gastric cancer	oncological	2 097 652
49	B.55.	Treatment of patients with colitis ulcerosis	non-oncological	1 837 395
50	B.53.	Treatment of well-differentiated neuroendocrine pancreatic carcinoma	oncological	1 766 397
51	B.26.	Treatment of mucopolysaccharidosis type iv (maroteaux-lamy syndrome)	non-oncological	1 728 893
52	B.87.	Treatment of idiopathic pulmonary fibrosis	non-oncological	1 671 679
53	B.84.	Lenalidomid for the treatment of patients with anemia depending on transformations in the course of myelodysplastic assemblies with low or indirect risk, risk associated with cytogenetic irregularity with 5q deletion	oncological	1 586 077
54	B.69.	Treatment with paricalcitol of secondary hyperparathyroidism in haemodialysis patients	non-oncological	1 529 137
55	B.76.	Treatment of tyrosinemia type 1 (ht-1)	non-oncological	1 499 983
56	B.78.	Treatment of primary immune deficiencies in adult patients with normal human immunoglobulin administered with human recombined hyaluronidase	non-oncological	1 389 103
57	B.60.	Treatment of gaucher's disease type 1	non-oncological	1 244 807
58	B.42.	Treatment of dwarf children with turner syndrome (ts)	non-oncological	1 032 587
59	B.20.	Treatment of dwarf children with severe primary igf-1 deficiency	non-oncological	887 751
60	B.27.	Treatment of chronic lung infections in beneficiaries with mucoviscidosis	non-oncological	832 382
61	B.65.	Treatment of acute lymphoblastic leukemia	oncological	826 749
62	B.30.	Treatment of spasticity in cerebral palsy	non-oncological	810 558

Lp.	Number of drug program	Name of drug program	Type	Values of reimbursement realised by the NHF, [USD]
63	B.37.	Treatment of anaemia in the course of chronic renal insufficiency	non-oncological	778 431
64	B.57.	Treatment of upper limb spasticity after stroke with botulinum toxin type a	non-oncological	762 256
65	B.66.	Treatment with bexarotene of mycosis fungoides or sézary syndrome	oncological	736 061
66	B.88.	Treatment of patients with advanced basocellular skin cancer wismodegib	oncological	609 818
67	B.85.	Treatment of patients with metastatic pancreatic adenocarcinoma	oncological	603 611
68	B.18.	Treatment of premature sexual maturation in children	non-oncological	478 466
69	B.75.	Treatment of active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa)	non-oncological	475 941
70	B.64.	Treatment with growth hormone of dwarf children born too small in relation to pregnancy length (sga or iugr)	non-oncological	409 770
71	B.49.	Oral treatment of iron overload states in the body	non-oncological	372 776
72	B.52.	Treatment of squamous cell cancer of head and neck	oncological	364 229
73	B.41.	Treatment of prader-willi syndrome	non-oncological	207 472
74	B.43.	Treatment of viral hepatitis b in beneficiaries after transplantations or in beneficiaries with lymphomas, treated with rituximab	non-oncological	186 964
75	B.38.	Treatment of dwarf children with chronic kidney failure	non-oncological	114 339
76	B.83.	Treatment of lower limb spasticity after stroke with botulinum toxin type a	non-oncological	89 713
77	B.82.	Treatment of certolizumab pegol patients with heavy, active form of axial spondyloartropathy (spa) without radiographic changes	non-oncological	69 770
78	B.21.	Treatment of severe familial hyperhomocysteinemia	non-oncological	63 785
79	B.89.	Treatment with ewerolimus of patients with sclerosis tuberosa non-qualifying for operative treatments with <i>subependymal</i> giant cells (sega)	oncological	52 467
80	B.61.	Treatment of nephropathic juvenile cystinosis	non-oncological	39 084
81	B.86.	Treatment of congenitated auto-inflammatory assemblies	non-oncological	36 356
82	B.90.	Treatment of motor disorders in the course of advanced parkinson's disease	non-oncological	17 303

Lp.	Number of drug program	Name of drug program	Type	Values of reimbursement realised by the NHF, [USD]
83	B.73.	Treatment of neurogenic detrusor overactivity	non-oncological	13 543

Source: own elaboration, NHF data.

REIMBURSEMENT BY DRUG PROGRAMME TYPE IN POLAND ESTIMATES TO 2018

Appendix. 4. Reimbursement by drug programme type in Poland estimates to 2018, [USD].

Lp.	Number of drug program	Name of drug program	Type	Values of reimbursement realised by the NHF, [USD]
1	B.9.	Treatment of breast cancer	oncological	120 564 937
2	B.29.	Treatment of multiple sclerosis	non-oncological	74 570 625
3	B.71.	Interferon-free treatment of chronic viral hepatitis C	non-oncological	58 957 833
4	B.4.	Treatment of advanced colorectal cancer	oncological	46 374 846
5	B.54.	treatment of refractory or relapsed multiple myeloma	oncological	43 222 355
6	B.10.	Treatment of renal cell carcinoma	oncological	38 155 171
7	B.33.	Treatment of rheumatoid arthritis and aggressive juvenile idiopathic arthritis	non-oncological	35 534 988
8	B.59.	Treatment of skin or mucosal melanoma	oncological	32 643 073
9	B.14.	Treatment of chronic myeloid leukemia	oncological	29 714 120
10	B.31.	Treatment of pulmonary arterial hypertension (PAH)	non-oncological	26 660 996
11	B.56.	Treatment of castration-resistant prostate cancer	oncological	22 327 920
12	B.3.	Treatment of gastrointestinal stromal tumours (GIST)	oncological	22 273 244

Lp.	Number of drug program	Name of drug program	Type	Values of reimbursement realised by the NHF, [USD]
13	B.70.	Treatment of neovascular (exudative) form of age-related macular degeneration (AMD)	non-oncological	21 045 965
14	B.46.	Treatment of multiple sclerosis after first line treatment failure or rapidly evolving severe multiple sclerosis	non-oncological	20 021 314
15	B.36.	Treatment of beneficiaries with severe active ankylosing spondylitis with TNF alfa inhibitors	non-oncological	19 835 842
16	B.72.	Treatment of melanoma with combination therapy with dabrafenib and trametinib	oncological	18 463 676
17	B.6.	Treatment of non-small cell lung cancer	oncological	17 049 924
18	B.12.	Treatment of malignant lymphomas	oncological	15 579 222
19	B.67.	Treatment with immunoglobulin transfusions in neurologic diseases	non-oncological	15 333 074
20	B.23.	Treatment of Gaucher's disease	non-oncological	14 673 701
21	B.35.	Treatment of aggressive psoriatic arthritis	non-oncological	11 102 138
22	B.68.	Treatment of pulmonary arterial hypertension with sildenafil, epoprostenol and macitentan (pah)	non-oncological	10 909 480
23	B.32.	Treatment of crohn's disease (cd)	non-oncological	9 712 364
24	B.81.	Treatment of primary myelofibrosis and secondary myelofibrosis in the course of polycythemia and thrombocytosis	oncological	9 323 293
25	B.87.	Treatment of idiopathic pulmonary fibrosis	non-oncological	9 265 419
26	B.15.	Haemorrhages prevention in children with haemophilia a and b	non-oncological	8 739 265
27	B.1.	Treatment of chronic viral hepatitis b	non-oncological	8 684 694
28	B.48.	Treatment of skin melanoma	oncological	8 626 239
29	B.22.	Treatment of pompe disease	non-oncological	8 567 666
30	B.77.	Treatment of resistant and relapse lymphomas cd30+	oncological	7 935 812
31	B.80.	Maintenance therapy with olaparib of patients with relapsed platinum-sensitive advanced ovarian cancer,	oncological	7 755 700

Lp.	Number of drug program	Name of drug program	Type	Values of reimbursement realised by the NHF, [USD]
		fallopian tube cancer or primary peritoneal cancer		
32	B.50.	Treatment of patients with advanced ovarian cancer	oncological	7 391 638
33	B.40.	Prevention of respiratory syncytial virus infections	non-oncological	7 306 999
34	B.44.	Treatment of severe ige-dependent allergic asthma with omalizumab	non-oncological	6 977 968
35	B.19.	Treatment of dwarf children with somatotropin pituitary insufficiency	non-oncological	6 869 004
36	B.25.	Treatment of mucopolisacharosis type ii (hunter syndrome)	non-oncological	6 678 216
37	B.47.	Treatment of aggressive psoriatic arthritis	non-oncological	6 112 470
38	B.62.	Treatment of primary immunodeficiency in adults	non-oncological	5 549 987
39	B.79.	Treatment of chronic lymphocytic leukemia with obinutuzumab	oncological	5 514 203
40	B.74.	Treatment of chronic thromboembolic pulmonary hypertension (cteph)	non-oncological	4 589 063
41	B.84.	Lenalidomid for the treatment of patients with anemia depending on transformations in the course of mylodysplastic assemblies with low or indirect risk, risk associated with cytogenetic irregularity with 5q deletion	oncological	3 914 369
42	B.92.	Ibrutinib in the treatment of patients with chronic lymphocytic leukemia	oncological	3 768 442
43	B.8.	Treatment of soft tissue sarcomas	oncological	3 478 333
44	B.88.	Treatment of patients with advanced basocellular skin cancer wismodegib	oncological	3 438 567
45	B.39.	Treatment of secondary hyperparathyroidism in haemodialysis patients	non-oncological	3 218 567
46	B.63.	Treatment of non-small cell lung cancer with afatinib and nintedanib	oncological	3 076 843
47	B.95.	Treatment of atypical hemolytic-uremic syndrome (<i>ahus</i>)	non-oncological	3 048 972
48	B.96.	Treatment of paroxysmal nocturnal hemoglobinuria	non-oncological	3 022 699
49	B.5.	Treatment of hepatocellular carcinoma	oncological	2 855 103

Lp.	Number of drug program	Name of drug program	Type	Values of reimbursement realised by the NHF, [USD]
50	B.78.	Treatment of primary immune deficiencies in adult patients with normal human immunoglobulin administered with human recombinant hyaluronidase	non-oncological	2 852 819
51	B.24.	Treatment of Hurler disease	non-oncological	2 836 066
52	B.17.	Treatment of primary immunodeficiency in children	non-oncological	2 832 343
53	B.55.	Treatment of patients with ulcerative colitis	non-oncological	2 781 703
54	B.28.	Treatment of focal dystonia and hemifacial spasm	non-oncological	2 578 618
55	B.85.	Treatment of patients with metastatic pancreatic adenocarcinoma	oncological	2 329 798
56	B.58.	Treatment of advanced gastric cancer	oncological	2 262 861
57	B.53.	Treatment of well-differentiated neuroendocrine pancreatic carcinoma	oncological	1 731 430
58	B.69.	Treatment of secondary hyperparathyroidism in haemodialysis patients	non-oncological	1 513 055
59	B.60.	Treatment of gaucher's disease type i	non-oncological	1 422 153
60	B.26.	Treatment of mucopolysaccharidosis type IV (Maroteaux-Lamy syndrome)	non-oncological	1 334 243
61	B.76.	Treatment of tyrosinemia type 1 (ht-1)	non-oncological	1 271 372
62	B.20.	Treatment of dwarf children with severe primary igf-1 deficiency	non-oncological	1 135 330
63	B.42.	Treatment of dwarf children with Turner syndrome (TS)	non-oncological	1 059 483
64	B.2.	Treatment of chronic viral hepatitis C	non-oncological	1 057 169
65	B.27.	Treatment of chronic lung infections in beneficiaries with mucoviscidosis	non-oncological	885 183
66	B.57.	Treatment of upper limb spasticity after stroke with botulinum toxin type a	non-oncological	867 516
67	B.65.	Treatment of acute lymphoblastic leukemia	oncological	849 380
68	B.30.	Treatment of spasticity in cerebral palsy	non-oncological	786 463

Lp.	Number of drug program	Name of drug program	Type	Values of reimbursement realised by the NHF, [USD]
69	B.89.	Treatment with ewerolimus of patients with sclerosis tuberosa non-qualifying for operative treatments with <i>subependymal</i> giant cells (sega)	oncological	772 851
70	B.64.	Treatment with growth hormone of dwarf children born too small in relation to pregnancy length (sga or iugr)	non-oncological	749 597
71	B.37.	Treatment of anaemia in the course of chronic renal insufficiency	non-oncological	731 097
72	B.66.	Treatment with beksarotene of mycosis fungoides or sézary syndrome	oncological	718 945
73	B.90.	Treatment of motor disorders in the course of advanced parkinson's disease	non-oncological	611 303
74	B.75.	Treatment of active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa)	non-oncological	523 936
75	B.82.	Treatment of certolizumab pegol patients with heavy, active form of axial spondyloarthritis without radiographic changes	non-oncological	509 266
76	B.18.	Treatment of premature sexual maturation in children	non-oncological	507 553
77	B.83.	Treatment of lower limb spasticity after stroke with botulinum toxin type a	non-oncological	450 700
78	B.93.	Pixsantron for the treatment of malignant lymphoma	oncological	427 712
79	B.97.	Treatment of adults with idiopathic thrombocytopenic purpura	non-oncological	352 674
80	B.100.	Treatment of resistant and recurrent form of hodgkin's classic lymphoma using niwolumab	oncological	259 071
81	B.86.	Treatment of congenitally auto-inflammatory disorders	non-oncological	243 684
82	B.52.	Treatment of squamous cell cancer of head and neck	oncological	224 321
83	B.41.	Treatment of prader - willi syndrome	non-oncological	220 229
84	B.49.	Oral treatment of iron overload states in the body	non-oncological	219 311
85	B.98.	Treatment of pediatric patients with chronic primary immunothrombocytopenia	non-oncological	215 894
86	B.43.	Treatment of viral hepatitis B in beneficiaries after transplantations or in beneficiaries with lymphomas, treated with rituximab	non-oncological	170 902
87	B.91.	Treatment of severe immunoresistant pemphigus with rituximab	non-oncological	144 466
88	B.99.	Treatment of acromegaly with pasipathide	non-oncological	103 823
89	B.38.	Treatment of dwarf children with chronic kidney failure	non-oncological	102 225

Lp.	Number of drug program	Name of drug program	Type	Values of reimbursement realised by the NHF, [USD]
90	B.21.	Treatment of severe familial hyperhomocysteinemia	non-oncological	54 227
91	B.61.	Treatment of nephropathic juvenile cystinosis	non-oncological	18 842
92	B.73.	Treatment of neurogenic detrusor overactivity	non-oncological	9 815

Source: own elaboration, NHF data.